Skip to main content
Log in

Comparison of International Regulations for Written Medicine Information (WMI) on Prescription Medicines

  • Global Perspectives: Review
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

This paper presents a review of the literature, including government legislations, policies, guidelines, and recommendations available in the European Union, the United States of America, and Australia pertaining to the availability, development, and distribution of written medicine information (WMI) for prescription medicines. The online databases searched were Embase, International Pharmaceutical Abstracts, Medline, and PubMed, together with Google as the Internet search engine. The design and content of WMI documents have similarities and differences across all the 3 geographical regions. All the 3 regions have legislations in place to evaluate and regulate WMI documents for health care professionals (HCPs) and, to some degree, for patients; however, the degree of regulation varies between the 3 regions. The regulations around the content and information design of WMI impacts how well the WMI performs and consequently influences patients’ knowledge and medication-taking behavior. Legislation in certain areas could be seen as more beneficial and can be implemented across the 3 regions. Furthermore, the required legislation on the evaluation of the content of WMIs can be seen in some areas to be more stringent and comprehensive, which when taken onboard across the 3 regions can be valuable when creating WMIs for both patients and HCPs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aslani P. The Use of Consumer Medicine Information by Community Pharmacists. Sydney: Faculty of Pharmacy, University of Sydney; 2000.

    Google Scholar 

  2. Hamrosi KK. Identifying the Barriers and Facilitators to the Use of Written Medicine Information by Community Pharmacists, General Practitioners and Consumers. Sydney: Faculty of Pharmacy, The University of Sydney; 2014.

    Google Scholar 

  3. Koo MMS. The Use of Written Medicine Information by Consumers. Sydney: Faculty of Pharmacy, The University of Sydney; 2005.

    Google Scholar 

  4. European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. http://ec.europa.eu/health/files/eudralex/vol-2/c/2009_01_12_readability_guideline_final_en.pdf. Published 2009. Accessed July 14, 2014.

  5. US Food and Drug Administration. The FDA announces new prescription drug information format. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm188665.htm. Published 2006. Accessed September 17, 2014.

  6. National Association of Chain Drugstores, National Community Pharmacists Association, Institute FM et al. Citizen petition: requesting FDA action on a “one document solution” for all pharmacy-based communications. https://www.pharmamedtechbi.com/∼/media/Images/Publications/Archive/The%20Pink%20Sheet/71/010/00710100020/single_pharmacy_leaflet_petition.pdf. Published 2008. Accessed August 31, 2015.

  7. US Food and Drug Administration. Labeling for human prescription drug and biological products—implementing the PLR content and format requirements. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075082.pdf. Published 2013. Accessed September 28, 2014.

  8. US Food and Drug Administration. Guidance—useful written consumer medication information (CMI). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080602.pdf. Published 2006. Accessed September 28, 2014.

  9. US Food and Drug Administration. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products—content and format (I). http://www.fda.gov/downloads/Drugs/Guidances/ucm075096.pdf. Published 2011. Accessed September 28, 2014.

  10. US Food and Drug Administration. Hypertension indication: drug labeling for cardiovascular outcome claims. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm075072.pdf. Published 2011. Accessed September 28, 2014.

  11. US Food and Drug Administration. Contents of a complete submission for the evaluation of proprietary names (I). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm075068.pdf. Published 2010. Accessed September 28, 2014.

  12. US Food and Drug Administration. Content and format of the dosage and administration section of labeling for human prescription drug and biological products (I). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075066.pdf. Published 2010. Accessed September 28, 2014.

  13. US Food and Drug Administration. Updating labeling for susceptibility test information in systemic antibacterial drug products and antimicrobial susceptibility testing devices (I). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM169359.pdf. Published 2009. Accessed September 28, 2014.

  14. US Food and Drug Administration. Labeling for human prescription drug and biological products—determining established pharmacologic class for use in the highlights of prescribing information (I). http://www.fda.gov/downloads/Drugs/Guidances/ucm186607.pdf. Published 2009. Accessed September 28, 2014.

  15. US Food and Drug Administration. Indexing structured product labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072317.pdf. Published 2008. Accessed September 20, 2014.

  16. US Food and Drug Administration. Clinical studies section of labeling for human prescription drug and biological products: content and format (I). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127534.pdf. Published 2006. Accessed September 28, 2014.

  17. US Food and Drug Administration. Adverse reactions section of labeling for human prescription drug and biological products; content and format (I). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm075057.pdf. Accessed September 28, 2014.

  18. US Food and Drug Administration. Content and format for geriatric labeling (I). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075062.pdf. Published 2001. Accessed September 28, 2014.

  19. Nathan JP, Zerilli T, Cicero LA, Rosenberg JM. Patients’ use and perception of medication information leaflets. Ann Pharmacother. 2007;41:777–782. http://journals.sagepub.com/doi/abs/10.1345/aph.1H686?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed. Accessed September 28, 2014.

    Article  Google Scholar 

  20. US Food and Drug Administration MedWatch: The FDA Safety Information and Adverse Event Reporting Program 2015. http://www.fda.gov/Safety/MedWatch/default.htm. Accessed June 4, 2015.

  21. DAILYMED. Provides trustworthy information about marketed drugs. http://dailymed.nlm.nih.gov/dailymed/index.cfm. Published 2014. Accessed September 20, 2014.

  22. US Food and Drug Administration. Guidance—medication guides—distribution requirements and inclusion in Risk Evaluation and Mitigation Strategies (REMS). http://www.fda.gov/downloads/Drugs/…/Guidances/UCM244570.pdf. Published 2011. Accessed August 28, 2015.

  23. US Food and Drug Administration. Guidance for industry—Medication Guides—adding a toll-free number for reporting adverse events. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm164669.pdf. Published 2009. Accessed August 29, 2015.

  24. Wolf MS, King J, Wilson EAH, et al. Usability of FDA-approved medication guides. J Gen Intern Med. 2012;27:1714–1720.

    Article  Google Scholar 

  25. Engelberg Center for Health Care Reform at Brookings. Exploring the promise of patient medication information. http://www.brookings.edu/∼/media/events/2014/07/pmi-meeting-71—agenda-and-discussion-guide.pdf. Published 2014. Accessed August 19, 2014.

  26. Pearsall BM, Araojo R, Hinton D. Essential medication information for patients: ensuring access. Therapeutic Innovation & Regulatory Science. 2013;48:162–164.

    Article  Google Scholar 

  27. Brennan Z. FDA discusses upcoming proposed rule on one-page patient medication information. http://www.raps.org/Regulatory-Focus/News/2017/02/23/26945/FDA-Discusses-Upcoming-Proposed-Rule-on-One-Page-Patient-Medication-Information/. Published 2017. Accessed August 19, 2017.

  28. Vander Stichele RH, Vander Bogaert MG. European legislation and research projects regarding patient education for medication. Drug Inf J. 1995;29:285–290.

    Article  Google Scholar 

  29. Kenny T, Wilson RG, Purves IN, Clark J Sr, Newton LD, Moseley DV. A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Fam Pract. 1998;15:471–479.

    Article  CAS  Google Scholar 

  30. EUR-Lex. Labelling and package leaflets for medicinal products. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISSUM:l32006. Published 1992. Accessed June 4, 2015.

  31. Vander Stichele RH, Van haecht CH, Braem MD, Bogaert MG. Attitude of the public toward technical package inserts for medication information in Belgium. DICP. 1991;25:1002–1006.

    Article  Google Scholar 

  32. Morris LA, Tabak ER, Gondek K. Counseling patients about prescribed medication: 12 year trends. Med Care. 1997;35:996–1007.

    Article  CAS  Google Scholar 

  33. European Commission. EudraLex. Volume 2: Pharmaceutical legislation notice to applicants and regulatory guidelines medicinal products for human use. http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm. Published 2014. Accessed July 12, 2014.

  34. European Commission. EudraLex. Volume 2C: Regulatory guidelines. http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm. Published 2014. Accessed July 12, 2014.

  35. European Medicines Agency. Product-information templates. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000134.jsp&mid=WC0b01ac0580022c59. Published 2014. Accessed July 12, 2014.

  36. Committee for Human Medicinal Product. Guideline on declaration of storage conditions: A: In the product information of medicinal products. B: For active substances. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003468.pdf. Published 2007. Accessed July 13, 2014.

  37. Committee for Human Medicinal Product. Note for guidance on Maximum shelf-life for sterile product for human use after first opening or following reconstitution. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003476.pdf. Published 1998. Accessed July 13, 2014.

  38. European Commission. A guideline on summary of product characteristics (SmPC). http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Published 2009. Accessed July 13, 2014.

  39. European Medicines Agency. How to prepare and review a summary of product characteristics 2012; http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2012/07/WC500130008.pdf Accessed July 25, 2014.

  40. European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf. Published 2012. Accessed July 15, 2014.

  41. Raynor DK, Knapp P, Silcock J, Parkinson B, Feeney K. “User-testing” as a method for testing the fitness-for-purpose of written medicine information. Patient Educ Couns. 2011;83:404–410.

    Article  Google Scholar 

  42. Jay E, Aslani P, Raynor DK. User testing of consumer medicine information in Australia. Health Educ J. 2010;70:420–427.

    Article  Google Scholar 

  43. European Medicines Agency. Linguistic review. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000131.jsp&mid=WC0b01ac0580022c57. Published 2014. Accessed July 25, 2014.

  44. European Medicines Agency. Mock-ups and specimens. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000131.jsp&mid=WC0b01ac0580022c57. Published 2014. Accessed July 30, 2014.

  45. European Medicines Agency. Product information: Reference documents and guidelines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000254.jsp&mid=WC0b01ac058008c34c. Published 2014. Accessed July 30, 2014.

  46. European Medicines Agency. Tables of non-standard abbreviations. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004439.pdf. Published 2012. Accessed July 25, 2014.

  47. European Medicines Agency. Compilation of QRD decisions on stylistic matters in product information. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004442.pdf. Published 2014. Accessed July 25, 2014.

  48. European Medicines Agency. Compilation of QRD decisions on use of terms. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004443.pdf. Published 2011. Accessed July 30, 2014.

  49. European Medicines Agency. QRD convention to be followed for the EMA-QRD templates. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500005091.pdf. Published 2011. Accessed July 30, 2014.

  50. European Agency for the Evaluation of Medicinal Products. Version 0.11: Addressing the paediatric or incapacitated patient in the package leaflet. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004461.pdf. Published 2000. Accessed July 30, 2014.

  51. European Medicines Agency. QRD recommendations on the expression of strength in the name of centrally authorised human medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500056428.pdf. Published 2009. Accessed July 30, 2014.

  52. European Commission. Excipients in the label and package leaflet of medicinal products for human use. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004296.pdf. Published 2003. Accessed July 30, 2014.

  53. Electronic Medicine Compendium. eMC. https://www.medicines.org.uk/emc/. Published 2017. Accessed March 15, 2015.

  54. Luto Research. Patient information leaflet “shortcomings” report published. http://luto.co.uk/news/patient-information-leaflet-shortcomings-report-published. Published March 16, 2016. Accessed November 7, 2017.

  55. European Commission. Subject: Summary of comments to the study report on the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC): Agenda item 6a. https://ec.europa.eu/health//sites/health/files/files/committee/75meeting/pharm699_6a_pil_and_smpc_doc.pdf. Published 2015. Accessed November 7, 2017.

  56. European Commission. Study on the package leaflets and the summaries of product characteristics of medicinal products for human use: PIL-S study. https://ec.europa.eu/health//sites/health/files/files/committee/75meeting/pil_s.pdf. Published 2014. Accessed November 7, 2017.

  57. Therapeutic Goods Administration. Guidance 8: product information. http://www.tga.gov.au/guidance-8-product-information. Published 2017. Accessed March 15, 2015.

  58. Therapeutic Goods Administration. Form for providing product information for a restricted medicine or other medicine in relation to which the secretary requires product information to be provided. http://www.tga.gov.au/form-providing-product-information. Published 2017. Accessed June 2, 2015.

  59. GuildLink. Powering the better use of medicines. http://www.guildlink.com.au. Published 2015. Accessed June 2, 2015.

  60. US Food and Drug Administration. Consumer medication information (CMI): expert and consumer evaluation of consumer medication information: questions and answers. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ReportsBudgets/ucm163786.htm. Published 2008. Accessed January 15, 2017.

  61. US Food and Drug Administration. Minutes of the Risk Communication Advisory Committee, FDA. February 26-27, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/UCM152593.pdf. Accessed February 3, 2017.

  62. Aslani P, Hamrosi KK, Feletto E, et al. Investigating Consumer Medicine Information (I-CMI) project. The Pharmacy Guild of Australia 2010.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hsiu-Chun Tony Yuan BSc, MMedSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, HC.T., Raynor, D.K. & Aslani, P. Comparison of International Regulations for Written Medicine Information (WMI) on Prescription Medicines. Ther Innov Regul Sci 53, 215–226 (2019). https://doi.org/10.1177/2168479018776949

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018776949

Keywords

Navigation